TScan Therapeutics, Inc. TCRX
0.15 USD +0.01 (+4.07%)
Regular-session close
0.16 +0.01 +5.96%
After hours · Nov 17, 4:04 PM ET
0.1403 Day range 0.1592
0.1403 52-week range 1.47
- YTD
- -84.90%
- 1 year
- -84.43%
News
benzinga.com TScan Therapeutics Q3 EPS $(0.25) Misses $(0.19) Estimate, Sales $586.000K Beat $459.000K Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 10.71 percent increase over losses…
globenewswire.com TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumors Advancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates for solid tumors through…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA)…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
